Harrow, Inc. (HROW) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $35.50: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 8.90; Below-average business quality.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused... Read more
Sell if holding. Engine safety override at $35.50: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 8.90; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 69. Score 4.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 61d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Harrow, Inc.
Latest news
- NEWS Earnings Preview: Harrow to Report Financial Results Post-market on May 11 - Moomoo — Moomoo neutral
- NEWS Harrow Health (HROW) Reports Q1 Earnings Miss with Shares Down 9 - GuruFocus — GuruFocus negative
- NEWS Is Harrow (HROW) Pricing Reflect Its 65.5% One Year Surge And DCF Outlook - Yahoo Finance — Yahoo Finance positive
- NEWS Harrow Inc. (HROW) Stock Falls on Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative negative
- NEWS Harrow Inc. (HROW) stock falls on Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -5.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.50: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 8.90; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 69. Prior stop was $33.39. Score 4.5/10, moderate confidence.
Take-profit target: $58.94 (+64.2% upside). Prior stop was $33.39. Stop-loss: $33.39.
Quality below floor (3.4 < 4.0).
Harrow, Inc. trades at a P/E of N/A (forward 12.5). TrendMatrix value score: 7.0/10. Verdict: Sell.
14 analysts cover HROW with a consensus score of 4.3/5. Average price target: $68.
What does Harrow, Inc. do?Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of...
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.